Serum growth hormone and insulin-like growth factor-I levels in fibromyalgia syndrome; [Fi̇bromyalji̇ sendromlu hastalarda serum growth hormon ve insulin-like growth faktör-I düzeyleri̇]
No Thumbnail Available
Date
2000
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
It has been hypothesized that depressed levels of Insulin-Like Growth Factor-I (Somatomedin C) (IGF-I), caused by a deficit of stage-4-sleep-dependent release of Growth Hormone (GH) may play role in pathophysiology and muscle pain in fibromyalgia syndrome (FMS). In this study we aimed to measure the serum levels of GH and IGF-I in patients with FMS and to investigate the relationship between GH and IGF-I levels and clinical features. The study included 32 female patients with FMS and 22 age and sex matched healthy controh. Two way radioimmunoassay method was used to measure serum concentrations of IGF-I and chemiluminans method was used to measure GH. Visual Analog Scale (VAS) was used for subjective assessment of pain and sleep disturbance. Mann-Whitney U test and Pearson Correlation Analysis were used for statistical analysis. The mean serum levels of GH (0,36±0,63 ng/ml in fibromyalgia group and 0,97±1,11 ng/ml in control group) and IGF-I (107.38±25.32 ng/ml in fibromyalgia group and 174.50±41.52 ng/ml in control group) were significantly lower in fibromyalgia group (p<0.001). But there were no statistically significant correlation between sleep disturbance, intensity of general pain, intensity of pain after physical activity, intensity of resting pain, intensity of pain with palpation, intensity of morning stiffness, number of tender points, tender points, tender point palpation scores, Beck Depression Scale scores, Hamilton Depression Rating Scale scores and State Anxiety inventory scores with serum levels of IGF-I and GH. We concluded that the disruption of GH and IGF-I secretion may play role in the pathophysiology of FMS however it does not effect the intensity of clinical findings.